AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
Antiemetic improves control of chemotherapy-induced nausea, vomiting.
2004 JAN 1 - (NewsRx.com & NewsRx.net) -- A post-hoc analysis of two Phase III trials for Emend (aprepitant) showed that treatment with Emend in combination with a 5-HT3 receptor antagonist and a corticosteroid ("regimen with Emend ") significantly improved emetic control in both women and men, and was generally well tolerated compared to a 5-HT3 receptor antagonist and a corticosteroid alone ("control regimen").
Emend is antiemetic given in oral capsule form developed by Merck & Co., Inc. Study data were presented on December 8, 2003, at the 26th Annual San Antonio Breast Cancer Symposium.
Although women generally experience more nausea and vomiting after undergoing chemotherapy, women have not responded as well as men have to antiemetic therapies in large, randomized studies using highly emetogenic chemotherapy (i.e., chemotherapy that causes most patients to vomit if they do not receive anti-vomiting medicines prior to treatment). This new analysis showed that Emend in combination with standard antiemetics provided similar efficacy for both women and men, in both the acute (day 1) and delayed (days 2 through 5) phases of nausea and vomiting.
"In this analysis, with the addition of Emend, we saw equal protection from nausea and vomiting in both women and men," reported Richard J. Gralla, MD, president, Multinational Association of Supportive Care in Cancer (MASCC). "This is the first study to demonstrate equal protection from nausea and vomiting in both genders."
The multi-center, randomized, double-blind, placebo-controlled clinical trials evaluated 1,043 patients (435 female; 608 male) who were randomly assigned to one of ...
- FDA Approves EMEND(R) (fosaprepitant dimeglumine) for Injection, Merck's New...
- Press release article from: Business Wire January 29, 2008 700+ words
...warfarin) may need to have blood tests after taking EMEND for Injection or oral EMEND to check their blood clotting. Women who use birth control medicines during treatment with EMEND for Injection and oral EMEND and for up to one month after...
- FDA Approves EMEND -aprepitant-, Merck's New Medicine to Prevent Nausea and...
- Press release article from: Business Wire March 26, 2003 700+ words
...Food and Drug Administration (FDA) has approved EMEND(R) (aprepitant). EMEND (EE-mend), the first member in a new class...Clinical Research, Merck Research Laboratories. "EMEND is a new medicine that will help more patients to...
- New Analysis Showed Regimen with EMEND Reduced Impact of Chemotherapy-Triggered...
- Press release article from: Business Wire June 2, 2003 700+ words
...from two of the Phase III trials for EMEND(R) (aprepitant). The analyses showed treatment with a regimen with EMEND (taken with a 5-HT3 receptor antagonist...vomiting medicines prior to treatment. EMEND is a new medicine approved for use in...
- Emend.(NEW & APPROVED)(Drug overview)
- Magazine article from: Internal Medicine News Mechcatie, Elizabeth October 1, 2006 700+ words
Emend (aprepitant, Merck) A substance P/neurokinin...of anesthesia. * Special Considerations: Emend is a weak to moderate CYP3A4 inhibitor...astemizole, or cisapride. * Comment: Emend blocks N[K.sub.1] receptors in the...
- Plavix, emend.(New & Approved)
- Magazine article from: Skin & Allergy News Mechcatie, Elizabeth November 1, 2006 700+ words
...000 Americans have a STEMI every year. Emend (aprepitant, Merck) A substance P...anesthesia. * Special Considerations: Emend is a weak to moderate CYP3A4 inhibitor...astemizole, or cisapride. * Comment: Emend blocks [NK.sub.1] receptors in the...
- FDA Committee Reviews Data on EMEND, Merck's Drug for the Prevention of Nausea...
- Press release article from: Business Wire March 6, 2003 700+ words
...FDA) today reviewed clinical data on EMEND(R) (aprepitant), Merck & Co...advisory committee unanimously agreed that EMEND in combination with standard antiemetic...information about the safety profile of the EMEND regimen in patients receiving certain chemotherapeutic...
- Merck & Co's Emend cleared by FDA for nausea in cancer chemotherapy.
- Newspaper article from: Pharma Marketletter April 7, 2003 700+ words
...cautions related to the use of Emend, particularly with regard to drug interactions. Emend may interact with some chemotherapies...effectiveness of oral contraceptives. Women of child-bearing years should...of birth control when using Emend, the agency advises. "Patients...
- FDA OKs Merck & Co's Emend in combination.(Brief Article)
- Newspaper article from: Pharma Marketletter January 16, 2006 700+ words
...cause nausea and vomiting. Emend, in combination with other...cisplatin. The FDA approval for Emend is based on the findings of...patients, of whom 99.5% were women. The study compared a regimen including Emend (EMEND in combination with...